Oncolytics Biotech wins FDA Fast Track status for pelareorep in second-line anal cancer

Reuters2026/07/20 13:08

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncolytics Biotech won FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or later anal cancer.
Designation covers inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal following prior systemic therapy.
GOBLET study data cited an objective response rate near 30% with a median duration of response about 15.5 months.
Oncolytics pegged the U.S. opportunity at about USD 1 billion a year, citing no FDA-approved options post first-line standard of care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200900PRIMZONEFULLFEED9764534) on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncolytics Biotech wins FDA Fast Track status for pelareorep in second-line anal cancer

You may also like

Crypto prices